T cells can be directed to antigen-specific, MHC-independent target cell lysis by grafting with a recombinant receptor with antibody-like specificity. Here, we asked whether T cells from the peripheral blood of a patient with cutaneous T cell lymphoma can be recruited for an immune response against autologous tumor cells. Lymphoma cells with a CD3
T cells can be equipped with pre-defined binding specificity by grafting with a recombinant receptor that harbors an antibody-derived binding domain and an intracellular signalling domain for cellular activation. The chimeric receptor strategy combines the universal properties of antibodies for specific antigen recognition with highly efficient cellular activation upon antigen-specific receptor crosslinking. To test this strategy for use in the cellular immunotherapy of malignant diseases, a number of in vitro and in vivo systems have been applied. Most of these systems have in common that cells of established tumor cell lines were utilized as a model system (Refs 1-3, for review see Ref. 4) . On the other hand, it was recently demonstrated that primary, in situ growing tumors and transplanted tumor cell lines differ substantially in their ability to induce a cellular antitumor response and that tumor cell lines may poorly reflect the clinical situation. 5 Particularily, in situ growing autologous tumor cells are partially or completely tolerized by the immune system and an efficient antitumor response is frequently suppressed during tumor progression. Accordingly, in the case of melanoma substantial populations of tumor-specific CD8 + cytotoxic T cells (CTLs) could be detected despite tumor progression. Tumorspecific CTLs, however, were demonstrated to be functionally anergized 6 and, moreover, melanoma-specific CTLs, that were successfully generated by peptid vaccination, did not induce significant tumor regression. 7 On the other hand, the cellular anergy seems to be restricted to tumor-specific CTLs because viral antigens induce a normal cellular immune response in these patients. 6 From this situation arises the question of whether T cells from the peripheral blood of a tumor patient whose immune functions are not yet substantially affected by the malignant disease can be recruited for an immune response against the autologous tumor cells. To address this issue we engrafted peripheral blood T cells of a patient suffering from a CD30 + cutaneous T cell lymphoma with a recombinant receptor molecule that has binding specificity for the CD30 antigen. The antigenbinding site of the receptor is composed of an anti-CD30 single chain antibody fragment (HRS3-scFv) that was fused to the transmembrane and intracellular domains of the high affinity IgE receptor signalling chain (Fc⑀RI␥). The CD30 target-antigen is a 120 kDa glycoprotein of the TNF/nerve growth factor receptor family 8 that is predominantly expressed on Hodgkin-and some non-Hodgkin lymphomas and on virus-infected lymphocytes. A small subpopulation of normal activated lymphocytes in lymphatic tissues, predominantly around B cell follicles and the edge of germinal centers in lymph nodes and spleen, express CD30 whereas resting lymphocytes do not. 9 It was suggested that CD30 may be involved in the negative selection of thymocytes. 10 However, CD30-lacking mice do not show an altered primary or secondary B cell and T cell response, respectively. 10 Due to its highly restricted expression pattern on malignant and virusinfected cells and on a small proportion of activated T and B cells, the CD30 antigen is a suitable target for an antibody-based immunotherapy. While the binding specificity and the functional activity of the recombinant anti-CD30-␥ immunoreceptor was previously shown in detail, 11 we demonstrate here that receptor-grafted peripheral blood T cells of a patient with a cutaneous T cell lymphoma are specifically activated against autologous tumor cells mediating a MHC-independent, CD30-specific cellular immune response that is highly effective even at very low effector to target cell ratios.
Suspension cells were isolated from a biopsy of a cutaneous T cell lymphoma lesion. Flow cytometric analysis revealed a predominant cell population with a CD3 − CD4 + CD30 + phenotype in addition to low numbers of normal cells (Figure 1a, b 
addition of exogeneous IL-2, characterized by two-color immunofluorescence utilizing FITC-conjugated anti-CD4, anti-CD25 or anti-CD30 mAbs and phycoerythrin-(PE)-conjugated anti-CD4 or anti-CD3 mAbs, respectively (all Dako, Hamburg, Germany). The cells were analyzed in a FACScan cytofluorometer (Becton Dickinson, Mountain View, CA, USA). Dead cells were stained by propidium iodide (Sigma, Deisenhofen, Germany) and excluded from analysis. (a-c) Two-color immunofluorescence analysis of cells from the lymphoma lesion. (d) Histogramm analysis of CD3 + T cells from the lymphoma lesion. CD3 + T cells from (c) were gated and the percentage of CD25
+ cells was determined.
the CD3 − CD4 + CD30 + phenotype could not be detected in the patient's peripheral blood either by flow cytometry or by clone-specific PCR (data not shown). We conclude that the lymphoma lesion harbors one predominant cell clone specified by clonal V␤7-J␤2.7 TCR rearrangement and a CD3 − CD4 + CD30 + phenotype suggesting that this cell population represents the malignant cell clone. Moreover, due to the lack of CD3 expression, the lymphoma cells differ phenotypically from infiltrating normal CD3 + T lymphocytes. To determine whether the latter represent activated or resting T cells we monitored the number of IL-2 receptor (CD25) expressing CD3
+ cells present within the lymphoma lesion. Strikingly, about 23% of normal CD3 + T cells derived from the lymphoma biopsy express the IL-2 receptor (Figure 1c, d) indicating the presence of a high number of activated T cells.
We asked whether anti-CD30-␥ immunoreceptorgrafted T cells from the lymphoma patient's peripheral blood are specifically activated against autologous CD30 + lymphoma cells. Therefore, the patient's peripheral blood lymphocytes and for comparison six healthy donors were engrafted by retroviral gene transfer with the recombinant anti-CD30 receptor HRS3-scFv-␥ and the anti-CEA receptor BW431/26-scFv-Fc-␥, respectively. Recombinant receptor-expressing T cells were identified by flow cytometry utilizing receptor-specific anti-idiotypic and anti-CD3 mAbs. Retroviral transduction of the lymphoma patient's peripheral blood T cells resulted in about 5% of T cells expressing the recombinant receptor whereas the transduction rates of healthy donors were in the range of 4% to 40% (Table 1) − CD30 + and CD3 − CD4 + phenotype. Figure 3 shows exemplarily a dot blot analysis of receptor-grafted T cells that were co-incubated with initially equal numbers of autologous CD30 + lymphoma cells; Figure 4 summarizes the data of these experiments. a,b The generation of the CEA-specific BW431/26-scFv-Fc-␥ and the CD30-specific HRS3-scFv-␥ receptor was recently described. 11, 14 For retroviral transduction of peripheral blood T cells, the receptor expression cassette (HRS3-scFv-␥; BW431/26-scFv-Fc-␥) was inserted into the retroviral vector pSTITCH. 15, 16 To generate GALVpseudotyped retrovirus, 293T cells were cotransfected with the recombinant pSTITCH vector DNA (6 g) and with DNA of the retroviral helper plasmids pHIT and pCOLT (each 6 g DNA/ml), encoding the MMLV gag and pol genes and the GALV envelope gene, respectively. 13 This procedure results in transient production of high titers of infectious retrovirus. Peripheral blood lymphocytes were isolated by density centrifugation and cultured for 48 h in RPMI 1640 medium supplemented with 10% (v/v) FCS (both Life Technologies, Paisley, UK), 400 U/ml IL-2 (Endogen, Woburn, MA, USA) and 100 ng/ml anti-CD3 mAb (OKT3; ATCC CRL 8001) that was purified from hybridoma supernatants by binding to protein A. For retroviral transduction, cells of six randomly selected donors and of a patient with a cutaneous T cell lymphoma, respectively, were harvested, resuspended in medium with 400 U/ml IL-2, and co-cultured for 48 h with transfected 293T cells. Recombinant receptor-grafted allogeneic T cells of this donor were cocultivated with primary cutaneous T lymphoma cells. d Expression of recombinant receptors was monitored utilizing antiidiotypic mAbs as follows: receptor-grafted T cells were incubated with 10 g/ml of the anti-idiotypic mAb 9G10 (anti-HRS3-scFv-␥), the anti-idiotypic mAb BW2064/36 (anti-BW431/26-scFv-Fc-␥) (both IgG1), 17, 18 and 2.5 g/ml of the anti-CD3 mAb OKT3 (IgG2a). Bound antibodies were subsequently detected by a FITC-conjugated F(ab′) 2 anti-mouse IgG1 antibody and a PE-conjugated F(ab′) 2 anti-mouse IgG2a antibody, respectively (each 1 g/ml) (both Southern Biotechnology, Palo Alto, CA, USA).
CD3
− CD4 + CD30 + lymphoma cells are specifically eliminated in the presence of autologous HRS3-scFv-␥ receptorgrafted T cells but not in the presence of nontransduced or anti-CEA-␥ receptor-grafted autologous T cells. Taking into account the transduction rate of about 5%, the cell ratio of 1:1 actually represents a ratio of about one anti-CD30-␥ receptor-expressing T cell to 20 lymphoma cells. Strikingly, this effector:target (E:T) ratio resulted in specific lymphoma cell depletion of more than 95% of the control within 72 h. Moreover, even a cell ratio of 0.2:1 representing an E:T ratio of 1:100 still resulted in depletion of lymphoma cells of about 30-40% of control (Figure 4) . The cytolysis is specific because nontransduced and anti-CEA-␥ receptor-transduced autologous T cells had no substantial effect. In addition to depletion of CD3 − CD30 + lymphoma cells, CD30-specific targeting also resulted in depletion of normal CD3 + CD30 + T cells (Figure 3d Taken together, our data indicate that (1) CD25 + activated T cells are present within the cutaneous lymphoma lesion (cf. Figure 1 ) and (2) cells derived from the lymphoma lesion secrete the Th1 cytokine IFN-␥. However, clinical progression of the tumor occurred despite the presence of high numbers of activated T cells and a tumor environment that seems to be favorable for a cellular immune response. Moreover, in vitro cocultivation of lymphoma cells with normal autologous lymphocytes from the peripheral blood that were pre-activated by treatment with an anti-CD3 mAb (OKT3) plus IL-2 did not induce efficient lymphoma cell depletion (Figures 3,  4) . In this experimental situation, IL-2-mediated cellular activation of normal blood lymphocytes is not sufficient to revert tolerance against autologous lymphoma cells and to induce a cellular antitumor response. In contrast, engraftment of autologous peripheral blood T cells with an anti-CD30-␥ receptor resulted in highly efficient, MHC-independent targeting of the autologous CD30 + lymphoma cells. The recruitment of receptor-grafted peripheral blood T cells may substitute anergized tumorspecific CTLs that seem to persist in tumor patients. 6 Moreover, the anti-CD30-␥ receptor-mediated cellular immune response against autologous tumor cells is highly efficient even at E:T cell ratios of as low as 1:20, implying serial cytolysis of autologous target cells without evidence of substantial T cell exhaustion. Evidence for serial cytolysis of target cells by receptor-grafted T cells was also reported for an allogeneic system. 19 It is essential for therapeutic efficacy that grafted T cells are capable of repeated cytolysis of target cells since the individual transduction rates differ remarkably dependent on the T cell donor. Antigen-driven T cell proliferation will, at least partially, compensate for low transduction rates. On the other hand, we recently demonstrated that anti-CD30-␥ receptor grafted T cells can be substantially enriched after retroviral transduction utilizing an antiidiotypic mAb with specificity for the receptor's antigen binding domain. 15 Enriched receptor-grafted T cells can be further expanded by short-term culture thereby significantly increasing the number of effector cells for clinical application. Based on the data presented in this report we conclude that anti-CD30-␥ receptor-grafted peripheral blood T cells can be recruited to direct a highly effective and specific antitumor response against autologous CD30 + lymphoma cells. This strategy may be promising to overcome T cell tolerance for autologous tumor cells.
